Ignite Creation Date:
2024-05-05 @ 11:03 PM
Last Modification Date:
2024-10-26 @ 10:28 AM
Study NCT ID:
NCT01245660
Status:
TERMINATED
Last Update Posted:
2013-01-11
First Post:
2010-11-18
Brief Title:
A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
Sponsor:
University Hospital Bordeaux
Organization:
University Hospital Bordeaux
Study Overview
Official Title:
Pilot Study of Lapatinib Tyverb in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy
Status:
TERMINATED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The rythm of enrollment was not compatible with the objective of recruitement in the research
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LAPAINBLAD
Brief Summary:
Modification of the EGF signalling pathway and or HER 2 by Lapatinib in bladder cancer
Detailed Description:
Patients with invasive bladder tumor candidates for radical cystectomy Patients will receive Lapatinib during 3 weeks - 5 days before cystectomy A comparison of tissue from the original biopsy and cystectomy after Lapatinib will allow this to occur
TREATMENT AND STRATEGY Lapatinib in bladder carcinoma -Overall there are arguments for considering that egf pathway is involved in bladder carcinoma and so far that drugs inhibiting EGF pathway could have an impact for therapeutical endpoints
Nevertheless it is unclear that from previous studies that adding egf inhibiting drug to chemotherapy is clinically relevant essentially by difficulties to measure a beneficial endpoint while downstream EGF pathways have been modified by these drugs as shown with lapatinib see 215
Furthermore there is no argument for initial selection of patients based on the initial egfr andor her 2 tumor profile asking for more intense knowledge
LAPATINIB TREATMENT Patients will receive lapatinib therapy at a daily standard dose of 1500 mg
LAPATINIB TREATMENT DURATION Patients will then receive 3 weeks of lapatinib therapy possible 5 days As the study is a non direct benefit study the exposition to the drug is proposed during the standard window of 3 to 4 weeks to organize a radical cystectomy in patients with muscle invasive bladder carcinoma In this study patients the standard procedure is not delayed for the purpose of the study
The duration of exposition to lapatinib as to be long enough to have a continuous impact of biological events to induce indeed inhibition of EGF pathway but also to impact on more complex or more distal events as apoptosis and so to be able to measure it This justifies a 3 weeks of treatment possible up to 5 days more due to surgical organization procedures
Surgery will take place on the last day of treatment which is recommended due to the half-life of lapatinib Nevertheless for surgical purpose the drug could be not given on the day of surgery
TREATMENT AND STRATEGY Lapatinib in bladder carcinoma -Overall there are arguments for considering that egf pathway is involved in bladder carcinoma and so far that drugs inhibiting EGF pathway could have an impact for therapeutical endpoints
Nevertheless it is unclear that from previous studies that adding egf inhibiting drug to chemotherapy is clinically relevant essentially by difficulties to measure a beneficial endpoint while downstream EGF pathways have been modified by these drugs as shown with lapatinib see 215
Furthermore there is no argument for initial selection of patients based on the initial egfr andor her 2 tumor profile asking for more intense knowledge
LAPATINIB TREATMENT Patients will receive lapatinib therapy at a daily standard dose of 1500 mg
LAPATINIB TREATMENT DURATION Patients will then receive 3 weeks of lapatinib therapy possible 5 days As the study is a non direct benefit study the exposition to the drug is proposed during the standard window of 3 to 4 weeks to organize a radical cystectomy in patients with muscle invasive bladder carcinoma In this study patients the standard procedure is not delayed for the purpose of the study
The duration of exposition to lapatinib as to be long enough to have a continuous impact of biological events to induce indeed inhibition of EGF pathway but also to impact on more complex or more distal events as apoptosis and so to be able to measure it This justifies a 3 weeks of treatment possible up to 5 days more due to surgical organization procedures
Surgery will take place on the last day of treatment which is recommended due to the half-life of lapatinib Nevertheless for surgical purpose the drug could be not given on the day of surgery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None